Am J Epidemiol. 2023 May 5;192(5):703-713. doi: 10.1093/aje/kwac164.
Arterial blood oxygen saturation as measured by pulse oximetry (peripheral oxygen saturation (SpO2)) may be differentially less accurate for people with darker skin pigmentation, which could potentially affect the course of coronavirus disease 2019 (COVID-19) treatment. We analyzed pulse oximeter accuracy and its association with COVID-19 treatment outcomes using electronic health record data from Sutter Health, a large, mixed-payer, integrated health-care delivery system in Northern California. We analyzed 2 cohorts: 1) 43,753 non-Hispanic White (NHW) or non-Hispanic Black/African-American (NHB) adults with concurrent arterial blood gas oxygen saturation/SpO2 measurements taken between January 2020 and February 2021; and 2) 8,735 adults who went to a hospital emergency department with COVID-19 between July 2020 and February 2021. Pulse oximetry systematically overestimated blood oxygenation by 1% more in NHB individuals than in NHW individuals. For people with COVID-19, this was associated with lower admission probability (-3.1 percentage points), dexamethasone treatment (-3.1 percentage points), and supplemental oxygen treatment (-4.5 percentage points), as well as increased time to treatment: 37.2 minutes before dexamethasone initiation and 278.5 minutes before initiation of supplemental oxygen. These results call for additional investigation of pulse oximeters and suggest that current guidelines for development, testing, and calibration of these devices should be revisited, investigated, and revised.
脉搏血氧饱和度(外周血氧饱和度 (SpO2))通过脉搏血氧仪测量,对于皮肤色素沉着较深的人来说,其准确性可能存在差异,这可能会影响 2019 年冠状病毒病 (COVID-19) 的治疗过程。我们使用加利福尼亚州北部大型混合支付方综合性医疗服务提供系统 Sutter Health 的电子健康记录数据,分析了脉搏血氧仪的准确性及其与 COVID-19 治疗结果的关系。我们分析了 2 个队列:1)2020 年 1 月至 2021 年 2 月期间同时进行动脉血气氧饱和度/SpO2 测量的 43,753 名非西班牙裔白人(NHW)或非西班牙裔黑人/非裔美国人(NHB)成年人;2)2020 年 7 月至 2021 年 2 月间因 COVID-19 前往医院急诊科的 8,735 名成年人。脉搏血氧仪在 NHB 个体中比在 NHW 个体中系统地高估了 1%的血液氧合作用。对于 COVID-19 患者,这与较低的入院概率(低 3.1 个百分点)、地塞米松治疗(低 3.1 个百分点)和补充氧气治疗(低 4.5 个百分点)相关,并且治疗开始的时间也延长了:地塞米松开始前 37.2 分钟和补充氧气开始前 278.5 分钟。这些结果呼吁对脉搏血氧仪进行进一步调查,并表明应重新审视、研究和修订这些设备的开发、测试和校准的现行指南。